Header Logo

Connection

STEVEN JAY FRANK to Prospective Studies

Back to Details
This is a "connection" page, showing publications STEVEN JAY FRANK has written about Prospective Studies.
STEVEN JAY FRANK
Connection Strength
1.020
Prospective Studies
  1. Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):614-625.
    View in: PubMed
    Score: 0.066
  2. Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
    View in: PubMed
    Score: 0.065
  3. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139.
    View in: PubMed
    Score: 0.064
  4. Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. JCO Oncol Pract. 2020 09; 16(9):e966-e976.
    View in: PubMed
    Score: 0.064
  5. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. Brachytherapy. 2018 Mar - Apr; 17(2):265-276.
    View in: PubMed
    Score: 0.055
  6. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
    View in: PubMed
    Score: 0.054
  7. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiother Oncol. 2016 12; 121(3):381-386.
    View in: PubMed
    Score: 0.050
  8. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.048
  9. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy. 2015 Mar-Apr; 14(2):160-5.
    View in: PubMed
    Score: 0.044
  10. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy. 2013 May-Jun; 12(3):210-6.
    View in: PubMed
    Score: 0.039
  11. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):401-7.
    View in: PubMed
    Score: 0.039
  12. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e765-71.
    View in: PubMed
    Score: 0.036
  13. Displacement of periurethral stranded seeds and its dosimetric consequences in prostate brachytherapy. Brachytherapy. 2011 Sep-Oct; 10(5):401-8.
    View in: PubMed
    Score: 0.034
  14. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5.
    View in: PubMed
    Score: 0.032
  15. The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta Oncol. 2022 Feb; 61(2):146-152.
    View in: PubMed
    Score: 0.018
  16. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 01; 44(1):158-167.
    View in: PubMed
    Score: 0.018
  17. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy. 2021 Nov-Dec; 20(6):1114-1129.
    View in: PubMed
    Score: 0.018
  18. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral Oncol. 2021 05; 116:105241.
    View in: PubMed
    Score: 0.017
  19. A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncol. 2020 07; 106:104665.
    View in: PubMed
    Score: 0.016
  20. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol. 2020 06; 147:64-74.
    View in: PubMed
    Score: 0.016
  21. Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Sci Data. 2020 02 21; 7(1):63.
    View in: PubMed
    Score: 0.016
  22. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
    View in: PubMed
    Score: 0.016
  23. Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):185-193.
    View in: PubMed
    Score: 0.015
  24. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903.
    View in: PubMed
    Score: 0.014
  25. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
    View in: PubMed
    Score: 0.014
  26. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
    View in: PubMed
    Score: 0.014
  27. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
    View in: PubMed
    Score: 0.013
  28. Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 07 01; 98(3):532-540.
    View in: PubMed
    Score: 0.013
  29. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.012
  30. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77.
    View in: PubMed
    Score: 0.011
  31. Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications? Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e299-308.
    View in: PubMed
    Score: 0.011
  32. Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg. 2014 Oct; 151(4):619-26.
    View in: PubMed
    Score: 0.011
  33. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol. 2014 May; 111(2):281-8.
    View in: PubMed
    Score: 0.011
  34. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
    View in: PubMed
    Score: 0.011
  35. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
    View in: PubMed
    Score: 0.010
  36. High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head Neck. 2013 Oct; 35(10):1490-8.
    View in: PubMed
    Score: 0.010
  37. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74.
    View in: PubMed
    Score: 0.008
  38. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1054-60.
    View in: PubMed
    Score: 0.008
  39. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1322-8.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.